Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals
Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals
复制标题
DOI：
10.1093/infdis/jiv004
复制
发表时间：
2015-08-01
影响因子：
6.4
通讯作者：
Mccomsey, Grace A.
中科院分区：
文献类型：
--
作者：
Hileman, Corrilynn O.;Kinley, Bruce;Mccomsey, Grace A.
背景关于不同的抗逆转录病毒药物如何影响人类免疫缺陷病毒（HIV）感染中的炎症和单核细胞活化，人们知之甚少。我们检查了在一项随机、双盲试验中获得的血浆标本，该试验在未经抗逆转录病毒治疗（ART）的HIV感染成人中进行，比较了埃替拉韦/可比司他/恩曲他滨/富马酸替诺福韦酯（EVG/c/FTC/TDF）与依法韦仑/恩曲他滨/富马酸替诺福韦酯（EFV/FTC/TDF）的疗效。从随机样本中获得HIV 1型RNA载量为
Background. Little is known about how different antiretrovirals effect inflammation and monocyte activation in human immunodeficiency virus (HIV) infection.Methods. We examined plasma specimens obtained during a randomized, double-blinded trial in antiretroviral therapy (ART)-naive HIV-infected adults which compared the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). From a random sample achieving an HIV type 1 RNA load of